Alliance for Pandemic Preparedness

May 24, 2021

Efficacy Estimates for Various COVID-19 Vaccines What We Know from the Literature and Reports

Category:

Topic:

Keywords (Tags): ,

  • [Pre-print, not peer-reviewed] A report using data from publications, reports, and press releases concluded that the average efficacy of the Pfizer-BioNTech, Moderna, Johnson & Johnson/Janssen, Oxford-AstraZeneca, Sputnik, Novavax, Sinovac, and Sinopharm vaccines was about 85% against any disease with infection. Vaccine efficacy was >80% for all vaccines included except for Sinovac (51%, 95% CI 36-62%). The average efficacy against severe disease, hospitalization or death was nearly 100%, and the average efficacy against infection, regardless of symptoms, was 84%. Additionally, the report found that the average vaccine efficacy against secondary transmission was 54%. Average efficacy against the different SARS-CoV-2 variants was 86% for B.1.1.7, 61% for B.1.1.28 or P1, and 56% for B.1.351.

Shapiro et al. (May 21, 2021). Efficacy Estimates for Various COVID-19 Vaccines What We Know from the Literature and Reports. Pre-print downloaded May 24 from https://doi.org/10.1101/2021.05.20.21257461